The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) by Boyko, Yaryna et al.
Vol.:(0123456789) 
Rheumatology International (2018) 38 (Suppl 1):S403–S409 
https://doi.org/10.1007/s00296-018-3983-7
VALIDATION STUDIES
The Ukrainian version of the Juvenile Arthritis Multidimensional 
Assessment Report (JAMAR)
Yaryna Boyko1 · Ihor Hrytsiuk1 · Alessandro Consolaro2,3 · Francesca Bovis2 · Nicolino Ruperto2 · For the Paediatric 
Rheumatology International Trials Organisation (PRINTO)
Received: 22 December 2017 / Accepted: 11 January 2018
© The Author(s) 2018. This article is an open access publication
Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Ukrainian 
language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating 
centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, 
floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct valid-
ity (convergent and discriminant validity). A total of 100 JIA patients (2% systemic, 44% oligoarticular, 20% RF-negative 
polyarthritis, 34% other categories) and 100 healthy children were enrolled at the paediatric rheumatology centre of the 
Western Ukrainian Specialised Children’s Medical Centre. The JAMAR components discriminated well between healthy 
subjects and JIA patients. Notably, there was no significant difference between healthy subjects and their affected peers in 
the school-related problems variable. All JAMAR components revealed good psychometric performances. In conclusion, 
the Ukrainian version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in 
routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Ukrainian parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient-
reported outcomes in JIA, including overall well-being, 
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functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Ukrainian language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from January 2015 to 
March 2015. Children were recruited after Ethics Committee 
approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, and 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 
three components: PF-lower limbs (PF-LL); PF-hand 
and wrist (PF-HW) and PF-upper segment (PF-US) 
each scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the physical health 
(PhH), and psychosocial health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to the international guidelines with 2–3 forward 
and backward translations. In those countries for which 
the translation of JAMAR had been already cross-cultural 
adapted in a similar language (i.e. Spanish in South Ameri-
can countries), only the probe technique was performed. 
Reading comprehension and understanding of the translated 
questionnaires were tested in a probe sample of 10 JIA par-
ents and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
the second Likert assumption or equal item–scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
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scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Ukrainian parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Ukrainian JAMAR was fully cross-culturally adapted 
from the standard English version with two forward and two 
backward translations with a concordance for 108/123 trans-
lations lines (87.8%) for the parent version and 106/120 lines 
(88.3%) for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the ten parents tested 
(median = 100%; range: 90–100%). All the 120 lines of the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range: 80–100%). Both 
versions of the JAMAR were unmodified after the probe 
technique.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 100 healthy children (total 
of 200 subjects) were enrolled at the paediatric rheumatol-
ogy centre of theWestern Ukrainian Specialised Children’s 
Medical Centre. One patient did not give the consent to use 
his/her data.
In the 100 JIA subjects, the JIA categories were 2% with 
systemic arthritis, 44% with oligoarthritis, 20% with RF-
negative polyarthritis, 3% with RF-positive polyarthritis, 1% 
with psoriatic arthritis, 16% with enthesitis-related arthritis 
and 4% with undifferentiated arthritis (Table 1).
A total of 186/200 (93%) subjects had the parent version 
of the JAMAR completed by a parent (100 from parents of 
JIA patients and 86 from parents of healthy children). The 
JAMAR was completed by 149/186 (80.1%) mothers and 
37/186 (19.9%) fathers. The child version of the JAMAR 
was completed by 131/200 (65.5%) children age 6.3 or older. 
Also patients younger than 7 years old, capable to assess 
their personal condition and able to read and write were 
asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the 
PF, the PhH, the PsH subscales and total score of the 
HRQoL scales. The JAMAR components discriminated 
well between healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers. However, there was no 
significant difference between healthy subjects and their 
affected peers in the school-related problems variable.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. Results 
refer mainly to the parent’s version findings, unless oth-
erwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did 
not allow to skip answers and input of null values. The 
response pattern for both PF and HRQoL was positively 
skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items except for items 1, 6, 8 and 9, whereas a 
reduced number of response choices was used for PF items 
from 6 to 11 and items 14 and 15.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items, 
except for HRQoL item 5 (data not shown). The median 
number of items marked as not applicable was 1% (0–1%) 
for the PF and 5% (5–10%) for the HRQoL.
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Table 1  Descriptive statistics (medians, 1st–3rd quartiles or absolute frequencies and %) for the 100 JIA patients
Data related to the JAMAR refer to the 100 JIA patients and to the 86 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. * p < 0.05, ** p < 0.001, # p < 0.0001
Systemic Oligoarthritis RF  poly-
arthritis
RF + poly-
arthritis
Psoriatic 
arthritis
Enthesitis-
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 12 N = 44 N = 20 N = 3 N = 1 N = 16 N = 4 N = 100 N = 100
Female 9 (75%) 32 (72.7%) 18 (90%) 3 (100%) 1 (100%) 1 (6.3%) 3 (75%) 67 (67%)** 63 (63%)
Age at visit 8.1 (6.3–11.9) 6.3 (3.8–10.7) 7.1 (5.1–10.3) 13.8 (11.2–
15.4)
2.9 (2.9–2.9) 15.4 (13–16.1) 16 (11.7–16.7) 8.9 (5.7–
13.5)#
9.7 (7.5–
11.7)
Age at onset 3.7 (2.1–4.1) 2.8 (1.6–5.6) 4.3 (2.4–7.2) 10.3 
(8.4–10.6)
1.1 (1.1–1.1) 12.7 
(9.8–14.5)
9.8 (4.7–15.8) 4.4 (2.3–9.3)#
Disease duration 4.7 (3.1–8.2) 2.5 (0.9–5.1) 2.7 (1.2–4.3) 4.8 (0.9–5.4) 1.8 (1.8–1.8) 1.5 (1–2.8) 1.9 (0.8–6.9) 2.6 (1–4.8)
ESR 6 (4–17.5) 6.5 (4–10) 7.5 (4.5–12.5) 6 (5–20) 15 (15–15) 15 (5–18.5) 12.5 (8–15.5) 7 (4–14)
MD VAS 3 (0–6) 0 (0–2) 1 (0–2) 0.5 (0–1) 2 (2–2) 0 (0–3) 1 (0–3) 0 (0–3)
No. of swollen 
joints
0 (0–14.5) 0 (0–1) 0 (0–1.5) 2 (0–3) 4 (4–4) 0 (0–2) 0 (0–0.5) 0 (0–1)
No. of joints with 
pain
1 (0–10.5) 0 (0–0) 1 (0–2) 0 (0–3) 0 (0–0) 0 (0–2) 0.5 (0–1.5) 0 (0–1)*
No. of joints with 
LOM
2 (0–13.5) 0 (0–1) 0 (0–1.5) 1 (0–8) 1 (1–1) 0 (0–0) 0 (0–1) 0 (0–1)*
No. of active joints 1 (0–15.5) 0 (0–1) 0 (0–1.5) 2 (0–3) 4 (4–4) 0 (0–2) 0 (0–0.5) 0 (0–1.5)
Active systemic 
features
2 (16.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (2%)
ANA status 1 (8.3%) 1 (2.3%) 1 (5%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (3%)
Uveitis 0 (0%) 4 (9.1%) 1 (5%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 5 (5%)
PF total score 1 (0–5) 0 (0–2) 2.5 (0–4.5) 1 (0–8) 0 (0–0) 0 (0–1) 2.5 (0–5) 0 (0–3) 0 (0–0)#
Pain VAS 1.5 (0.5–5) 0 (0–1) 0.5 (0–2.5) 0.5 (0.5–6) 0 (0–0) 1 (0.3–1.5) 1.8 (0.3–3.8) 0.5 (0–2) 0 (0–0)#
Disease activity 
VAS
1.8 (0.5–4.8) 0.5 (0–1.8) 1 (0–2.8) 0.5 (0.5–7) 0.5 (0.5–0.5) 0.8 (0.3–1) 2 (0.3–5) 0.5 (0–2)
Well-being VAS 1.8 (0.5–5.5) 0.5 (0–1.5) 1.5 (0.3–3) 1 (0–7.5) 1 (1–1) 0.8 (0–1.5) 2.5 (0.3–4.8) 1 (0–2)
HRQoL-PhH 3.5 (1–6) 1 (0–3) 2 (0–3.5) 1 (0–5) 0 (0–0) 1.5 (1–2.5) 1.5 (0–3.5) 1 (0–4) 0 (0–0)#
HRQoL-PsH 2.5 (1.5–3) 2 (0–4) 1 (0–2) 1 (0–3) 0 (0–0) 2 (1–2) 1 (0.5–2.5) 2 (0–3) 0 (0–0)#
HRQoL total score 5 (3.5–9.5) 3 (0–8) 3 (1.5–7) 1 (1–8) 0 (0–0) 3 (2–4) 2.5 (0.5–6) 3 (1–7) 0 (0–0)#
Pain/swell. in > 1 
joint
9 (75%) 22 (50%) 14 (70%) 2 (66.7%) 1 (100%) 9 (56.3%) 2 (50%) 59 (59%) 1 (1.2%)#
Morning stiff-
ness > 15 min
2 (16.7%) 3 (6.8%) 2 (10%) 0 (0%) 0 (0%) 1 (6.3%) 0 (0%) 8 (8%) 0 (0%)*
Subjective remis-
sion
6 (50%) 12 (27.3%) 10 (50%) 2 (66.7%) 0 (0%) 7 (43.8%) 2 (50%) 39 (39%)
In treatment 11 (91.7%) 43 (97.7%) 19 (95%) 3 (100%) 1 (100%) 13 (81.3%) 4 (100%) 94 (94%)
Reporting side 
effects
3/11 (27.3%) 7/43 (16.3%) 2/19 (10.5%) 1 (33.3%) 0 (0%) 2/13 (15.4%) 2 (50%) 17/94 (18.1%)
Taking medication 
regularly
11/11 (100%) 42/43 (97.7%) 19/19 (100%) 3 (100%) 1 (100%) 13/13 (100%) 4 (100%) 93/94 (98.9%)
With problems 
attending school
0 (0%) 1/18 (5.6%) 0 (0%) 0 (0%) – 0 (0%) 1 (25%) 2/51 (3.9%) 0 (0%)
Satisfied with dis-
ease outcome
8 (66.7%) 29 (65.9%) 8 (40%) 1 (33.3%) 1 (100%) 8 (50%) 2 (50%) 57 (57%)
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Floor and ceiling effect
The median floor effect was 91% (85–93%) for the PF 
items, 65% (54–70%) for the HRQoL-PhH items, and 58% 
(50–76%) for the HRQoL-PsH items. The median ceiling 
effect was 1% (0–2%) for the PF items, 4% (1–4%) for 
the HRQoL-PhH items, and 1% (1–2%) for the HRQoL-
PsH items. The median floor effect was 42% for the pain 
VAS, 32% for the disease activity VAS and 33% for the 
well-being VAS. The median ceiling effect was 1% for the 
pain VAS, 1% for the disease activity VAS and 0% for the 
well-being VAS.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 100/186 Child N = 53/131
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 91.0% 88.7%
 HRQoL-PhH 65.0% 73.6%
 HRQoL-PsH 58.0% 52.8%
 Pain VAS 42.0% 34.0%
 Disease activity VAS 32.0% 34.0%
 Well-being VAS 33.0% 34.0%
Ceiling effect, median
 PF 1.0% 0.0%
 HRQoL-PhH 4.0% 0.0%
 HRQoL-PsH 1.0% 0.0%
 Pain VAS 1.0% 0.0%
 Disease activity VAS 1.0% 0.0%
 Well-being VAS 0.0% 0.0%
Items with equivalent item–scale correlation 100% for PF, 100% for HRQoL 100% for PF, 70% for HRQoL
Items with item–scale correlation ≥ 0.4 100% for PF, 80% for HRQoL 73% for PF, 60% for HRQoL
Cronbach’s alpha
 PF–LL 0.85 0.71
 PF–HW 0.89 0.81
 PF–US 0.88 0.63
 HRQoL–PhH 0.87 0.81
 HRQoL–PsH 0.69 0.66
Items with item–scale correlation lower than the Cronbach’s alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.99 0.98
 HRQoL-PhH 0.79 0.48
 HRQoL-PsH 0.92 0.74
Spearman correlation with JIA core set variables, median
 PF 0.4 0.3
 HRQoL-PhH 0.5 0.5
 HRQoL-PsH 0.1 0.3
 Pain VAS 0.3 0.2
 Disease activity VAS 0.5 0.4
 Well-being VAS 0.5 0.3
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Equal item–scale correlations (second Likert 
assumption)
Pearson item–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 100% of the 
PF items and for 100% of the HRQoL items.
Items internal consistency (third Likert assumption)
Pearson item–scale correlations were ≥ 0.4 for 100% of 
items of the PF and 80% of items of the HRQoL (except 
for HRQoL items 9 and 10).
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.85 for PF-LL, 0.89 for PF-HW, and 
0.88 for PF-US. Cronbach’s alpha was 0.87 for HRQoL-PhH 
and 0.69 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after a 
median of 8 days (8–9 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC = 0.99). The ICC for the HRQoL-PhH 
showed a substantial reproducibility (ICC = 0.79) while the 
ICC for the HRQoL-PsH showed an almost perfect repro-
ducibility (ICC = 0.92).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.3 to 0.6 
(median = 0.4). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.7, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged from 
0.4 to 0.7 (median = 0.5), whereas for the PsH ranged from 
0 to 0.4 (median = 0.1). The PhH showed the best correla-
tion with the parent global assessment of well-being (r = 0.7, 
p < 0.001) and the PsH with the parent’s assessment of pain 
(r = 0.5, p < 0.001). The median correlations between the 
pain VAS, the well-being VAS, and the disease activity VAS 
and the physician-centred and laboratory measures were 0.3 
(0.2–0.4), 0.5 (0.4–0.6), 0.5 (0.3–0.7), respectively.
Discussion
In this study, the Ukrainian version of the JAMAR was 
cross-culturally adapted from the original standard Eng-
lish version with two forward and two backward transla-
tions. According to the results of the validation analysis, the 
Ukrainian parent and patient versions of the JAMAR possess 
satisfactory psychometric properties. The disease-specific 
components of the questionnaire discriminated well between 
patients with JIA and healthy controls. Notably, there was 
no significant difference between the healthy subjects and 
their affected peers in the school-related problems variable. 
This finding indicates that children with JIA adapt well to 
the consequences of JIA.
Psychometric performances were good for all domains 
of the JAMAR with few exceptions: two HRQoL items 
(difficulty in concentrating or paying attention and feeling 
dissatisfied with physical appearance or abilities) showed 
a lower items internal consistency. However, the overall 
internal consistency was good for all the domains (except 
for HRQoL-PsH where Cronbach’s alpha was questionable).
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from very weak to moderate.
Overall, the statistical performances of the child version 
of the JAMAR are somewhat poorer than those obtained 
by the parent version. The JAMAR is aimed to evaluate the 
side effects of medications and school attendance, which 
are other dimensions of daily life that were not previously 
considered by other HRQoL tools. This may provide useful 
information for intervention and follow-up in health care.
In conclusion, the Ukrainian version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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